Reishi Mushroom for Fatty Liver: Evidence & Safety

Reishi mushroom for fatty liver is a topic attracting growing interest, particularly among people looking to complement NHS-recommended lifestyle changes with natural supplements. Reishi (Ganoderma lucidum) is a medicinal fungus used in traditional East Asian medicine and is widely available in the UK as capsules, powders and extracts. While laboratory and animal studies have explored its potential antioxidant and lipid-modulating properties, the clinical evidence in humans remains limited. This article explains what fatty liver disease is, what current research shows about reishi, and what to discuss with your GP before considering it.

What is fatty liver disease and how is it managed on the NHS?

Fatty liver disease, including MASLD, is managed on the NHS primarily through lifestyle changes such as weight loss, a balanced diet and alcohol reduction, as recommended by NICE NG49. There is currently no medicine specifically licensed in the UK for MASLD.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, and it is broadly divided into alcohol-related liver disease (ARLD) and metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). MASLD is closely linked to obesity, type 2 diabetes, high cholesterol and insulin resistance, and is increasingly common in the UK. In its early stages it is often silent, but it can progress through stages of inflammation (steatohepatitis), fibrosis and, in some cases, cirrhosis.

NICE guidance (NG49) recommends that management of MASLD centres on lifestyle modification as the primary intervention. This includes achieving a sustained reduction in body weight (NICE NG49 cites a target of around 7 to 10 per cent of total body weight as associated with histological improvement), following a balanced diet, increasing physical activity and reducing or eliminating alcohol intake. The UK Chief Medical Officers advise keeping alcohol consumption to no more than 14 units per week, spread across three or more days, with alcohol-free days each week.^[1] There is currently no medicine specifically licensed in the UK for MASLD, although research into pharmacological treatments is ongoing.^[6][7]

Your GP can arrange blood tests, including liver function tests and a FIB-4 score, to help assess the degree of liver involvement. FIB-4 is widely used in UK primary care pathways, including those described in British Society of Gastroenterology (BSG) and British Association for the Study of the Liver (BASL) guidance on abnormal liver blood tests, and age-adjusted cut-offs are used to guide onward referral. NICE NG49 also describes the use of the NAFLD Fibrosis Score (NFS) and enhanced liver fibrosis (ELF) testing in secondary care.^[2][3] Ultrasound can identify steatosis (fat in the liver), while FibroScan measures liver stiffness as a marker of fibrosis; where available, the controlled attenuation parameter (CAP) function on FibroScan can also estimate the degree of steatosis. Referral to a hepatologist or specialist liver service is recommended for those with evidence of significant fibrosis or cirrhosis.

If you develop any of the following symptoms, seek urgent medical attention rather than waiting for a routine appointment: jaundice (yellowing of the skin or whites of the eyes), confusion or unusual drowsiness, vomiting blood or passing black tarry stools, or new or rapidly worsening abdominal swelling. These may indicate serious liver decompensation and require prompt assessment.

Regular monitoring is important because early-stage fatty liver disease is often reversible with appropriate lifestyle changes, whereas advanced disease carries a risk of serious complications including liver failure and hepatocellular carcinoma.

Can reishi mushroom actually help with fatty liver?

There is no robust clinical evidence that reishi mushroom can treat or reverse fatty liver disease in humans, and it is not licensed by the MHRA for this purpose. People with liver disease should exercise particular caution, as some supplements have been linked to drug-induced liver injury.

There is currently no robust clinical evidence that reishi mushroom (Ganoderma lucidum) can treat, reverse or meaningfully improve fatty liver disease in humans. Reishi is a medicinal fungus used in traditional East Asian medicine and is available in the UK as a food supplement in capsule, powder and extract forms. It is not a licensed medicine in the UK, and the MHRA has not authorised any reishi-based product for the treatment of liver disease.

Reishi contains several bioactive compounds, including polysaccharides, triterpenoids and beta-glucans, which have attracted scientific interest for their potential antioxidant and anti-inflammatory properties. In laboratory and animal studies, some of these compounds have shown effects on lipid metabolism and oxidative stress, both of which are relevant to the development of fatty liver. However, findings from cell cultures and rodent models do not reliably translate into clinical benefit in humans, and extrapolating such results to patient care requires considerable caution.

Because reishi products are sold as food supplements rather than medicines in the UK, they are not subject to the same rigorous pre-market safety and efficacy testing required of licensed medicines. The MHRA's guidance on borderline products sets out the distinction between medicines and food supplements, and the Food Standards Agency (FSA) provides advice on supplement quality and labelling. In practice, product quality, concentration of active compounds and purity can vary considerably between brands. Be cautious with high-dose extracts and multi-ingredient blends, and avoid products that make medicinal claims about treating or curing liver disease, as such claims are not permitted for food supplements under UK law.^[15][16]

People with liver disease should be particularly cautious, as some herbal and supplement products have themselves been associated with drug-induced liver injury. If you are considering reishi mushroom, discussing this with your GP or a registered dietitian before starting is strongly advisable.

What does the current research say about reishi and liver health?

Most evidence on reishi and liver health comes from animal and laboratory studies, with human trials limited by small sample sizes and poor standardisation. Pharmacovigilance data have also linked Ganoderma lucidum products to hepatotoxicity in some cases.

The existing research on reishi mushroom and liver health is at an early and largely preclinical stage, meaning that most evidence comes from laboratory experiments and animal studies rather than well-designed human clinical trials. Several animal studies have suggested that Ganoderma lucidum extracts may reduce hepatic fat accumulation, lower markers of liver inflammation and decrease oxidative stress in rodent models of fatty liver disease.^[9][11] These findings are biologically plausible given the antioxidant and lipid-modulating properties of reishi's active constituents.

A small number of human studies have examined reishi's effects on metabolic parameters such as blood glucose, cholesterol and liver enzymes, but these trials have generally been limited by small sample sizes, short durations, variable dosing and inconsistent product standardisation. Systematic reviews of the broader evidence base consistently note that the quality of available human data is insufficient to support firm recommendations for reishi supplementation in MASLD or ARLD.^[12] No large, randomised controlled trial has yet demonstrated a clinically meaningful benefit specifically for these conditions.

It is also worth noting that case reports and pharmacovigilance data, including summaries available through resources such as the LiverTox database, have linked Ganoderma lucidum products to hepatotoxicity, including elevated liver enzymes and, in rare cases, more serious liver injury.^[13] The mechanism is not fully understood, and it is unclear whether such reactions relate to the mushroom itself, contaminants or adulterants in poorly regulated products. Anyone who develops symptoms such as jaundice, persistent nausea, dark urine or right-sided abdominal discomfort after taking any supplement should stop taking it and contact their GP promptly. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme (yellowcard.^[17]mhra.gov.uk).

What should you discuss with your GP before trying reishi mushroom?

Tell your GP if you plan to take reishi, especially if you have fatty liver disease, take prescribed medicines such as anticoagulants or diabetes drugs, or have other health conditions. Reishi should not replace NICE-recommended lifestyle interventions for fatty liver disease.

Before trying reishi mushroom, you should inform your GP about your intention to use it, particularly if you have a confirmed diagnosis of fatty liver disease, are taking prescribed medicines or have any other underlying health conditions. This conversation matters because reishi may interact with certain medications, including anticoagulants such as warfarin, antiplatelet drugs and immunosuppressants. Some evidence suggests reishi can have mild blood-pressure-lowering and blood-glucose-lowering effects, which could be relevant if you are already taking medicines for hypertension or diabetes. If you are taking any of these medicines and still choose to use reishi, closer monitoring may be appropriate; your GP or pharmacist can advise.

If you are pregnant, planning a pregnancy or breastfeeding, you should avoid reishi mushroom supplements unless a clinician specifically advises otherwise. There are insufficient safety data in these groups to support use.

If you are due to have surgery or an invasive procedure, inform your surgical and anaesthetic teams about any supplements you are taking, including reishi. Because of its potential effects on bleeding, your clinical team may advise you to stop taking it before the procedure; follow their guidance on timing.

Your GP can also help you understand whether your liver disease has been adequately investigated and whether any lifestyle changes or monitoring are already recommended for you. It is important to be transparent about all supplements you are taking, as some can affect liver enzyme readings and complicate the interpretation of blood test results. If you have existing liver fibrosis or cirrhosis, the threshold for caution around any unregulated supplement is higher, and specialist hepatology advice may be appropriate before proceeding.

When choosing any supplement, look for products that carry a batch number, clear ingredient labelling and evidence of third-party testing for purity. Be aware that no reishi product in the UK carries a licensed medicinal claim for liver disease, and marketing language suggesting otherwise may not comply with UK advertising regulations.

Ultimately, the most evidence-based approach to managing fatty liver disease remains the lifestyle interventions recommended by NICE: sustained weight management, a balanced diet, regular physical activity and alcohol reduction. Reishi mushroom may be of interest as an area of ongoing research, but it should not replace these established strategies or any treatment plan agreed with your clinical team.

Frequently Asked Questions